Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma

Denileukin diftitox (Ontak(®)) is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL), a rare lymphoproliferative disorder of the skin. Denileukin diftitox was the first fusion protein toxin approved for the treatment of a human disease. This fusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Lansigan, Frederick, Stearns, Diane M, Foss, Francine
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2010
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004568/
https://www.ncbi.nlm.nih.gov/pubmed/21188096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3004568/
https://www.ncbi.nlm.nih.gov/pubmed/21188096

Ejemplares similares